Sustainable Chemistry 2023

An innovative 2 day meeting brings together a panel of over 150 prominent leaders and scientists, exploring Sustainable Chemistry, aiming to innovate processes to improve product performance whilst delivering environmental benefits.

Discuss the latest advancements in innovative approaches to sustainable drug development and manufacturing process.

Engage in scientific discussions paving the way towards sustainable chemical synthesis, analytical chemistry and chemical process development.

Dive into the latest technologies driving down pharma sector emissions by implementing “green-by-design” in early drug development phase pipeline projects.

Gain a comprehensive understanding of the peptides and oligonucleotides sustainability landscape; key sessions include application and technology areas.

Join a series of workshops, roundtables, and panel discussions to collaborate with your peers. 2023 sessions include: Greener Peptides, Green Chemical Synthesis, Chemistry in Water, Green Medicinal Chemistry and Green Manufacturing

Biologics 2023

Engage with esteemed pharmaceutical & biotech representatives as well as thought-leaders from academic & research institutions onsite and benefit from attending over 60 presentations. We will be welcoming onsite over 300 delegates for two days of cutting-edge scientific sessions and case studies bringing the latest biologics developments to the forefront of research

Immuno UK: In Person

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

Biomarkers 2023

Biomarkers 2023, designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.

It includes over 90 cutting-edge presentations and discussion sessions, 8+ hours of valuable networking sessions and an exhibition hall showcasing 50+ vendor companies.

Yogesh Goyal

Yogesh Goyal is an Assistant Professor of Cell & Developmental Biology at the Feinberg School of Medicine, Northwestern University. Yogesh received his B.Tech. with Honors in Chemical Engineering from the Indian Institute of Technology Gandhinagar, and his Ph.D. in Chemical and Biological Engineering focusing on quantitative developmental biology from Princeton University. Yogesh pursued postdoctoral work in single-cell systems and synthetic biology in Bioengineering at the University of Pennsylvania. Yogesh’s major honors include Burroughs Wellcome Fund CASI Award, Schmidt Science Fellowship, STAT Wunderkind, and the Jane Coffin Childs Fellowship. Yogesh’s group combines theory, computation, and single-cell resolved experiments to track and control cellular plasticity and fate choices in developing tissues and cancer.

Bojing Jiang

Synthetic Biology for Future Health

We are pleased to announce our new conference on synthetic biology. This conference will present how technologies from synthetic biology are delivering innovations across clinical health applications and leading towards improved global health.

The meeting will bring together researchers working on synthetic biology, biotechnology, genomics and medical sciences, along with industry members from pharma and biotech companies, and investors and funders in this growing research area. It will address how the technologies coming out of synthetic biology impact both advanced healthcare in developed countries (e.g. personalised medicines, T-cell therapies) and global wide-impact, such as very low-cost diagnostics and self-replicating living therapies. In addition, the conference aims to provide a reflection on where resources and work are succeeding and where more effort needs to be placed to ensure equitable global outcomes.

We aim to organise this meeting as a hybrid conference – with on-site or virtual attendance. If you would like to be part of these discussions – consider submitting an abstract by 17 January 2023 and register by 14 February (in-person) or 6 March (virtual) 2023.

To promote more inclusive scientific discussions with international colleagues at our conferences, virtual delegates based in Lower and Middle-Income Countries can register for free.

EBRC 2022 Council Retreat

Reminder to EBRC Council members in industry, government, and academia, to register and book your travel for the EBRC 2022 Council Meeting at J. Craig Venter Institute, in La Jolla, CA on November 7-8, 2022.

 

Travel Support and Meeting Hotel:
We anticipate covering airfare and hotel expenses for EBRC Academic Council Members. Please see EBRC’s full travel policy here.

EBRC has reserved a block of hotel rooms at the Embassy Suites by Hilton San Diego La Jolla at 4550 La Jolla Village Dr, San Diego, CA 92122 at $189.00 per night. Please indicate on the registration page if you will need hotel accommodations. We will reserve the room in our block. If your travel is not covered by EBRC, you can provide payment at check in. Please contact helix@ebrc.org with any questions rather than contacting the hotel directly.

Health and Safety:
We are committed to hosting a safe event. We will be closely watching CDC recommendations in addition to all relevant local and state guidelines leading up to the Meeting and make any changes necessary for health and safety. Proof of vaccination will be required for attendance. A rapid antigen testing strategy may also be deployed depending on conditions. Meals will be provided outside.

Jimmy Gollihar

I am a Scientist and Head of the Laboratory of Antibody Discovery & Accelerated Protein Therapeutics (ADAPT) at the Houston Methodist Research Institute (HMRI). My work encompasses a broad range of engineering biology, from the design of simple genetic “parts” and circuits to protein engineering and industrial biomanufacturing. I use a foundation in synthetic biology to domesticate non-model organisms and then use these tools and chasses to engineer proteins or biosynthetic pathways with therapeutic and industrial potential. I use a holistic approach to protein engineering by employing concepts in directed evolution, rational design, and artificial intelligence to create biological countermeasures, diagnostics, and vaccine candidates. Over the last few years, my group has been involved in the genomic surveillance and characterization of SARS-COV-2, B-cell repertoire mining for neutralization and protection assays, and the engineering of enzymes for use in mRNA vaccine manufacturing.

I also spent the last four years as a DoD scientist. In that time, I designed and built the Army’s Biological Foundry co-located at the University of Texas at Austin. This work increased DoD capability in the field of synthetic biology for early-stage research efforts. From 2019 to 2021, I also served as the government CTO of the Bioindustrial Manufacturing Innovation Institute– BioMADE. As the technical architect of the institute, I led the creation of a public-private partnership to develop innovations at scale for biological production of non-medical products. Prior to that, I led an in-house R&D effort in the private sector.

Jason Kang

Aaron Schaller

Aaron Schaller is a molecular biologist and entrepreneur with 10 years of experience in microbiology, molecular and cell biology, and immunology/virology. In May 2020 he co-founded MeliBio, Inc., a food company harnessing synthetic biology and medicinal plant science to produce the world’s first real honey without bees. Before starting MeliBio, Aaron completed his PhD at the University of California, Berkeley studying innate immunity in response to viral infection as an NSF graduate fellow. A combined passion for food, environmentalism, microbiology, and entrepreneurship led Aaron to co-found MeliBio, where he currently serves as CTO. Aaron believes that the future of planetary and human health lies in our ability to move away from animal-based food supplies towards more sustainable and logical options, and that microbiology can take us there.

Ryuichi Hirota

I am interested in the biosafety measure for the safer use of genetically modified bacteria. By controlling bacterial growth and survival using the engineered metabolic pathway for phosphorus, we developed novel biocontainment strategy which is robust, economical, and easy to apply.

Abhilash Patel

3D Cell Culture Online

Our 3D Cell Culture congress incorporates key trends and innovative technologies to accelerate the adoption of 3D models in preclinical research via advanced development, validation and application strategies.

Oligonucleotide Chemistry & Therapeutics Symposium

An intensive 1-day meeting that delves into the latest in oligonucleotides chemistry, process & analytical development, therapeutics, antisense therapy & a meeting place for experts working within cutting-edge oligo research & therapeutic development.

Luis Figueroa

Degree in Biology from the Universidad Veracruzana, Mexico. Master’s degree in Bioethics from the Anahuac University, Mexico. Doctorate in Sciences from the Scientific Research Center of Yucatán A.C., Mérida, Yucatán. Mexico. Postdoctoral fellow at the Donald Danforth Plant Science Center. St.Louis Missouri, United States.
Currently:
-Titular Type A Researcher at the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ), Zapopan Headquarters. Department of Industrial Biotechnology, Zapopan, Jalisco, Mexico. Distinction by the National System of Researchers (SNI I).
-General Coordinator of the “National Network of Synthetic Biology of Mexico”.
-Coordinator of the research sub-line “Synthetic Biology” within the Department of Industrial Biotechnology of the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ). In the working group, state-of-the-art sequencing (Oxford Nanopore Technologies) is performed in yeast and bioinformatic analysis of omics data (genome, transcriptome, metagenome). Design of transformation systems through synthesis and Gibson assembly. We use CRISPR-Cas9, dCas9 and Cas13, in order to edit or regulate genes to check functionality in cell lines of animals, bacteria, yeast, marine organisms and plants.

Meagan Olsen

Meagan is a PhD candidate in the Jewett and Karim Labs at Northwestern University. Her research focuses on improving cell-free protein synthesis systems in order to rapidly develop and manufacture medical therapeutics. She completed her B.S. in chemical engineering at the University of Arkansas. Outside of the lab, Meagan enjoys cooking, reading, quilting, and hiking.

Luis Figueroa-Yáñez

Degree in Biology from the Universidad Veracruzana, Mexico. Master’s degree in Bioethics from the Anahuac University, Mexico. Doctorate in Sciences from the Scientific Research Center of Yucatán A.C., Mérida, Yucatán. Mexico. Postdoctoral fellow at the Donald Danforth Plant Science Center. St.Louis Missouri, United States.
Currently:
-Titular Type A Researcher at the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ), Zapopan Headquarters. Department of Industrial Biotechnology, Zapopan, Jalisco, Mexico. Distinction by the National System of Researchers (SNI I).
-General Coordinator of the “National Network of Synthetic Biology of Mexico”.
-Coordinator of the research sub-line “Synthetic Biology” within the Department of Industrial Biotechnology of the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ). In the working group, state-of-the-art sequencing (Oxford Nanopore Technologies) is performed in yeast and bioinformatic analysis of omics data (genome, transcriptome, metagenome). Design of transformation systems through synthesis and Gibson assembly. We use CRISPR-Cas9, dCas9 and Cas13, in order to edit or regulate genes to check functionality in cell lines of animals, bacteria, yeast, marine organisms and plants.

Maxime Boneza

I am currently a third year PhD Candidate in the Biochemistry Molecular Biology and Biophysics (BMBB) program at the University of Minnesota Twin-Cities. Before I joined the BMBB program, I graduated from Southwestern University, in Georgetown Texas, with a Bachelor of Science in Chemistry in 2016. I then spent 3 years as a Lab Technician for Eco-Services in Houston Texas, which is a subsidiary of PQ Corporation specializing in sulfuric acid manufacturing.

Michaela Jones

Michaela is a postdoctoral researcher in Otto Cordero’s Lab at MIT working to expand the metabolic function of non-model ocean microbes. Prior to starting her postdoc, she completed her graduate work with Aditya Kunjapur at University of Delaware where she developed a new pathway for biosynthesis of non-standard amino acids and engineered a bacterial strain that was dependent on a non-standard amino acid for growth that can persist in soil microenvironments to build towards safely deployable synthetic microbes. As an EBRC board member, she serves as EMUMS chair to help provide academic mentorship to undergraduate and Master’s students interested in engineering biology.